{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Serum+Sample+Collection&page=7", "query": { "intervention": "Serum Sample Collection", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 562, "total_pages": 57, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Serum+Sample+Collection&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Serum+Sample+Collection&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T01:51:49.251Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01886872", "title": "Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage I Chronic Lymphocytic Leukemia", "Stage II Chronic Lymphocytic Leukemia", "Stage III Chronic Lymphocytic Leukemia", "Stage IV Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Bendamustine Hydrochloride", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 547, "start_date": "2014-01-15", "completion_date": "2027-06-24", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-19T01:51:49.251Z", "location_count": 917, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 596 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01886872" }, { "nct_id": "NCT03777904", "title": "The Iron Content of Ferritin in Serum and Urine of Children With High Serum Ferritin Levels", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Iron Overload" ], "interventions": [ { "name": "Serum Ferritin level", "type": "DIAGNOSTIC_TEST" }, { "name": "Serum Ferritin iron content", "type": "DIAGNOSTIC_TEST" }, { "name": "Urine Ferritin level", "type": "DIAGNOSTIC_TEST" }, { "name": "Urine ferritin iron content", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 11, "start_date": "2019-02-21", "completion_date": "2019-12-10", "has_results": false, "last_update_posted_date": "2022-04-05", "last_synced_at": "2026-10-19T01:51:49.251Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03777904" }, { "nct_id": "NCT07275216", "title": "Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Classic Hodgkin Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Physical Performance Testing", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Pulmonary Function Test", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2026-10-01", "completion_date": "2029-10-20", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-19T01:51:49.251Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07275216" }, { "nct_id": "NCT05136196", "title": "BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Locally Recurrent Head and Neck Squamous Cell Carcinoma", "Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Locally Recurrent Laryngeal Squamous Cell Carcinoma", "Locally Recurrent Oral Cavity Squamous Cell Carcinoma", "Locally Recurrent Oropharyngeal Squamous Cell Carcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hypopharyngeal Squamous Cell Carcinoma", "Metastatic Laryngeal Squamous Cell Carcinoma", "Metastatic Melanoma", "Metastatic Oral Cavity Squamous Cell Carcinoma", "Metastatic Oropharyngeal Squamous Cell Carcinoma", "Recurrent Melanoma", "Stage III Hypopharyngeal Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IV Hypopharyngeal Carcinoma AJCC v8", "Stage IV Laryngeal Cancer AJCC v8", "Stage IV Lip and Oral Cavity Cancer AJCC v8", "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Unresectable Melanoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2022-12-06", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-19T01:51:49.251Z", "location_count": 230, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 178 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05136196" }, { "nct_id": "NCT01533246", "title": "Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Prostate", "Hormone-resistant Prostate Cancer", "Recurrent Prostate Cancer", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "linsitinib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 17, "start_date": "2012-02", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2015-03-13", "last_synced_at": "2026-10-19T01:51:49.251Z", "location_count": 2, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01533246" }, { "nct_id": "NCT06866262", "title": "Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Clear Cell Renal Cell Carcinoma", "Locally Advanced Sarcomatoid Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Metastatic Sarcomatoid Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Inulin", "type": "DIETARY_SUPPLEMENT" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DIETARY_SUPPLEMENT", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2025-08-15", "completion_date": "2031-08-01", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-19T01:51:49.251Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06866262" }, { "nct_id": "NCT02408861", "title": "Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Anal Carcinoma", "HIV Infection", "Kaposi Sarcoma", "Lung Carcinoma", "Metastatic Malignant Solid Neoplasm", "Recurrent Classic Hodgkin Lymphoma", "Refractory Classic Hodgkin Lymphoma", "Unresectable Solid Neoplasm", "HIV-associated Cancers" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2015-10-21", "completion_date": "2024-08-31", "has_results": true, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-10-19T01:51:49.251Z", "location_count": 32, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 19 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02408861" }, { "nct_id": "NCT05672173", "title": "Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Transformed Chronic Lymphocytic Leukemia", "Refractory Transformed Chronic Lymphocytic Leukemia", "Richter Syndrome" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Lisocabtagene Maraleucel", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pheresis", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2023-06-02", "completion_date": "2027-08-24", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-19T01:51:49.251Z", "location_count": 2, "location_summary": "Duarte, California • New York, New York", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05672173" }, { "nct_id": "NCT04799275", "title": "Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Ann Arbor Stage III Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma", "Diffuse Large B-Cell Lymphoma Activated B-Cell Type", "Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Grade 3b Follicular Lymphoma", "HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Intravascular Large B-Cell Lymphoma", "Lymphoplasmacytic Lymphoma", "Nodular Lymphocyte Predominant B-Cell Lymphoma", "Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma", "Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Oral Azacitidine", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Rituximab and Hyaluronidase Human", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "75 Years", "maximum_age": null, "sex": "ALL", "summary": "75 Years and older" }, "enrollment_count": 422, "start_date": "2021-05-20", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-19T01:51:49.251Z", "location_count": 176, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 136 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04799275" }, { "nct_id": "NCT05642572", "title": "Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Capmatinib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2023-05-05", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-10-19T01:51:49.251Z", "location_count": 454, "location_summary": "Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 360 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Saraland", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05642572" } ] }